AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Respiratory or thoracic disease

non-small cell lung carcinoma

A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.

🔔 Follow weekly
🧬13555genes / proteins with evidence
💊1066drugs and clinical candidates
🧪12+recruiting trials worldwide
✅59approved
📈1filed for approval
🧬

Understand non-small cell lung carcinoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.

There are two main types: small cell lung cancer and non-small cell lung cancer. These two types grow differently and are treated differently. Non-small cell lung cancer is the more common type.

Who is more likely to develop lung cancer?

From MedlinePlus: Lung Cancer (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for non-small cell lung carcinoma itself.

🤖

AI briefing

Where the science on non-small cell lung carcinoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens non-small cell lung carcinoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
EGFR epidermal growth factor receptorPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.89
KRAS KRas proto-oncogene, GTPasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.83
ALK ALK receptor tyrosine kinasePROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.81
ERBB2 erb-b2 receptor tyrosine kinase 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.81
ROS1 ROS proto-oncogene 1, receptor tyrosine kinasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.81
MET MET proto-oncogene, receptor tyrosine kinasePROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.81
DICER1 dicer 1, ribonuclease IIIPROTAC🧊 AlphaFold structure ↗ 0.79
RET ret proto-oncogenePROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.78
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.77
BRAF B-Raf proto-oncogene, serine/threonine kinasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.76
ERBB4 erb-b2 receptor tyrosine kinase 4PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.76
EML4 EMAP like 4PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.75
STK11 serine/threonine kinase 11PROTACsmall molecule🧊 AlphaFold structure ↗ 0.74
KIF5B kinesin family member 5BPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.72
CCDC6 coiled-coil domain containing 6PROTACsmall molecule🧊 AlphaFold structure ↗ 0.72

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to non-small cell lung carcinoma, by how far it has got
Approved · 20
AdagrasibGTPase KRas inhibitorApproved
AfatinibEpidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2…Approved
Afatinib DimaleateEpidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2…Approved
AlectinibALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitorApproved
Alectinib HydrochlorideALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitorApproved
AmivantamabEpidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhib…Approved
Show all 20
Anamorelin HydrochlorideGhrelin receptor agonistApproved
AtezolizumabProgrammed cell death 1 ligand 1 inhibitorApproved
AumolertinibEpidermal growth factor receptor erbB1 inhibitorApproved
BevacizumabVascular endothelial growth factor A inhibitorApproved
BrigatinibALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitorApproved
CapmatinibHepatocyte growth factor receptor inhibitorApproved
Capmatinib HydrochlorideHepatocyte growth factor receptor inhibitorApproved
CeritinibALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitorApproved
CrizotinibHepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitorApproved
DacomitinibEpidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2…Approved
Datopotamab DeruxtecanTumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitorApproved
DocetaxelTubulin inhibitorApproved
DurvalumabProgrammed cell death 1 ligand 1 inhibitorApproved
EntrectinibNeurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase R…Approved
In phase 2 / 3 · 20
LenvatinibVascular endothelial growth factor receptor inhibitorFiled for approval
AbemaciclibCyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitorPhase 3
AbivertinibEpidermal growth factor receptor erbB1 inhibitor; Tyrosine-protein kinase BTK inhibitorPhase 3
Abivertinib MaleateEpidermal growth factor receptor erbB1 inhibitor; Tyrosine-protein kinase BTK inhibitorPhase 3
AcasunlimabPhase 3
AcetylcarnitinePhase 3
Show all 20
AdebrelimabProgrammed cell death 1 ligand 1 inhibitorPhase 3
AfliberceptVascular endothelial growth factor A inhibitor; Placenta growth factor inhibitorPhase 3
AgatolimodToll-like receptor 9 agonistPhase 3
Agatolimod SodiumToll-like receptor 9 agonistPhase 3
AmrubicinDNA topoisomerase II alpha inhibitorPhase 3
AnamorelinGhrelin receptor agonistPhase 3
AprinocarsenProtein kinase C alpha mRNA 3'UTR antisense inhibitorPhase 3
Ask-120067Phase 3
Astuprotimut-RMelanoma-associated antigen 3 vaccine antigenPhase 3
AteganosinePhase 3
AvelumabProgrammed cell death 1 ligand 1 otherPhase 3
BavituximabPhase 3
BecotatugPhase 3
BefotertinibPhase 3
Early trials · 20
AbequolixronLiver X receptor agonistPhase 1/2
Adg-106Phase 1/2
Aeg-35156Phase 1/2
AfuresertibSerine/threonine-protein kinase AKT inhibitorPhase 1/2
Ak-01Phase 1/2
AlisertibSerine/threonine-protein kinase Aurora-A inhibitorPhase 1/2
Show all 20
AlrizomadlinTumour suppressor p53/oncoprotein Mdm2 inhibitorPhase 1/2
Amg-820Macrophage colony stimulating factor receptor inhibitorPhase 1/2
AnakinraInterleukin-1 receptor antagonistPhase 1/2
Apg-1387Phase 1/2
ArtemisininPhase 1/2
ArtesunatePhase 1/2
AtamparibPhase 1/2
BafisontamabHepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhib…Phase 1/2
Bbp-398Phase 1/2
BelinostatHistone deacetylase inhibitorPhase 1/2
BempegaldesleukinPhase 1/2
BerzosertibSerine-protein kinase ATR inhibitorPhase 1/2
Bi-1206Phase 1/2
Bms-986148Phase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With …NCT06754644 · Phase 3 · 📍 JinanPrediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)NCT07388771 · n/a · 📍 WuhanA Real World Study of Ensartinib in Advanced ALK-positive NSCLCNCT05498064 · n/a · 📍 BeijingCardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving M…NCT05010109 · NA · 📍 HoustonA Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidat…NCT06424899 · Phase 2 · 📍 HangzhouAdaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)NCT07120698 · Phase 2 · 📍 GuangzhouStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 · Phase 1, Phase 2 · 📍 GilbertStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449 · Phase 1, Phase 2 · 📍 Los AngelesMolecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inh…NCT06107608 · NA · 📍 BrusselsTIL Therapy in Non-small-cell Lung Cancer (NSCLC) PatientsNCT06455917 · Phase 2 · 📍 BaselORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation…NCT06775743 · Phase 2 · 📍 ShanghaiTo Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung CancerNCT07195084 · NA · 📍 Hefei Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy